Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Biogen (BIIB)

Biogen expects $34 million Q1 2026 R&D charge, cutting EPS by $0.19 per share

Negative Impact 3 of 5 earnings Written later

Biogen said its first-quarter 2026 GAAP and non-GAAP results will include about $34 million in pre-tax acquired in-process research and development, upfront and milestone expense. The company said the charge will reduce net income per diluted share by about $0.19. Quarter results are not final and may differ from these preliminary estimates.

Key points

  • Expected pre-tax charge of approximately $34 million for acquired in-process R&D, upfront and milestone expense in Q1 2026
  • Estimated impact of approximately $0.19 per diluted share on both GAAP and non-GAAP net income
  • Quarter ended March 31, 2026 results have not been finalized and remain subject to closing procedures

The filing

CompanyBiogen (BIIB)
Form8-K, current report
Filed with the SECApr 6, 2026, 6:31 AM ET
Accession number0000875045-26-000039

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:30 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.